In 2014, Saxenda became the first GLP-1 analog approved for weight loss, and in 2021, semaglutide (Wegovy), became the second GLP-1 analog to receive this indication
It is classified as a multi-receptor peptide agonist because it has been studied for activity across three related receptor systems: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor
At which 0.1mL (10 units on U-100 syringe) delivers 0.5mg peptide
Inject Slowly and Steadily Push the needle in using a steady and slow motion
For starters, the blend does not contain any sugar, instead including OnoSweeta zero-calorie sweetener made from fermented rice thats considerably sweetener than table sugar
Personalized weight loss treatment, including a Compounded Sublingual Semaglutide 15mL